Université de Bordeaux, Pharmacochimie EA 4138, Bordeaux, France.
Eur J Med Chem. 2010 Feb;45(2):831-9. doi: 10.1016/j.ejmech.2009.10.032. Epub 2009 Oct 29.
A series of nucleoside derivatives was obtained via heteroatom annulation of the amino oxazoline of D-(-)-arabinose. Unequivocal proofs for the stereostructure of some new arabinosyl pyrimidinone derivatives were obtained by X-ray structure analysis. These newly synthesized compounds were then evaluated for their cytostatic activity against murine leukemia (L1210), and human T-lymphocytes (Molt 4/C8 and CEM). Of all the compounds in the series, the protected silylated tricyclic fused pyrimidinone 10 showed the most significant antitumor activity against murine leukemia L1210 (IC(50)=6 microM), and human T-lymphocytes cells Molt 4/C8 (IC(50)=7.9 microM) and CEM/0 cell lines (IC(50)=7.5 microM). None of the compounds exhibited significant antiviral inhibitory activities.
通过 D-(-)-阿拉伯糖的氨基恶唑啉的杂原子环合,得到了一系列核苷衍生物。通过 X 射线结构分析获得了一些新的阿拉伯糖基嘧啶酮衍生物的立体结构的确切证明。然后,评估了这些新合成的化合物对小鼠白血病(L1210)和人 T 淋巴细胞(Molt 4/C8 和 CEM)的细胞抑制活性。在所研究的化合物中,受保护的硅基化三环稠合嘧啶酮 10 对小鼠白血病 L1210(IC(50)=6 μM)、人 T 淋巴细胞 Molt 4/C8(IC(50)=7.9 μM)和 CEM/0 细胞系(IC(50)=7.5 μM)表现出最显著的抗肿瘤活性。这些化合物均无明显的抗病毒抑制活性。